Unicycive Short Term Coverage Ratios from 2010 to 2025

UNCY Stock  USD 0.63  0.01  1.61%   
Unicycive Therapeutics Short Term Coverage Ratios yearly trend continues to be fairly stable with very little volatility. Short Term Coverage Ratios is likely to outpace its year average in 2025. During the period from 2010 to 2025, Unicycive Therapeutics Short Term Coverage Ratios regression line of annual values had r-squared of  0.49 and arithmetic mean of (215.15). View All Fundamentals
 
Short Term Coverage Ratios  
First Reported
2010-12-31
Previous Quarter
-1.2 K
Current Value
-1.1 K
Quarterly Volatility
439.58357259
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 89.6 K, Net Interest Income of 493.9 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Unicycive Therapeutics Correlation against competitors.
For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Latest Unicycive Therapeutics' Short Term Coverage Ratios Growth Pattern

Below is the plot of the Short Term Coverage Ratios of Unicycive Therapeutics over the last few years. It is Unicycive Therapeutics' Short Term Coverage Ratios historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Term Coverage Ratios10 Years Trend
Slightly volatile
   Short Term Coverage Ratios   
       Timeline  

Unicycive Short Term Coverage Ratios Regression Statistics

Arithmetic Mean(215.15)
Geometric Mean5.39
Coefficient Of Variation(204.31)
Mean Deviation331.00
Median(0.74)
Standard Deviation439.58
Sample Variance193,234
Range1.2K
R-Value(0.70)
Mean Square Error104,692
R-Squared0.49
Significance0
Slope(64.92)
Total Sum of Squares2.9M

Unicycive Short Term Coverage Ratios History

2025 -1109.68
2024 -1168.08
2023 -1015.72
2022 -100.97
2021 -38.19
2020 -0.58
2019 -2.56

About Unicycive Therapeutics Financial Statements

Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' Short Term Coverage Ratios, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short Term Coverage Ratios-1.2 K-1.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.